Lactococcus Lactis LB1022 for NF-kB-Linked Inflammation Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases, such as inflammatory bowel disease, often involve immunosuppressive drugs that cause side effects, and there is a need for natural alternatives that effectively inhibit inflammatory factors without adverse reactions.
Innovation Solution
A novel strain of Lactococcus lactis subsp. lactis LB1022, isolated from fermented dairy products, exhibits excellent acid and bile tolerance, adheres to intestinal epithelial cells, and inhibits the production of inflammatory factors like NO, TNF-α, IFN-γ, and IL-1β by suppressing the NF κB pathway, offering compositions with live or dead bacteria or their culture medium for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunosuppressive drugs are used to treat inflammatory diseases, then therapeutic effects are achieved, but side effects such as nausea, heartburn, headache, dizziness, anemia, and skin rashes occur
Solution Approach 1:
The patent introduces lactic acid bacteria as an intermediary substance that mediates the treatment of inflammatory diseases. Instead of using direct immunosuppressive drugs, the bacteria act as a natural mediator that produces beneficial metabolites and modulates the immune system, thereby achieving therapeutic effects while avoiding the harmful side effects associated with conventional drugs.
Solution Approach 2:
The patent replaces the chemical/pharmaceutical system (immunosuppressive drugs) with a biological system (lactic acid bacteria). This substitution involves using living organisms and their metabolic products to achieve therapeutic effects, thereby eliminating the need for synthetic chemicals that cause side effects like nausea, heartburn, and skin rashes.
2Reliability
If conventional treatments for inflammatory diseases are used, then inflammation is suppressed, but the complexity of treatment and potential for adverse reactions increases
Solution Approach 1:
The patent extracts the essential therapeutic function from complex pharmaceutical interventions and concentrates it into a single biological agent - lactic acid bacteria. By taking out the core anti-inflammatory activity and expressing it through a natural organism rather than multiple chemical compounds, the treatment becomes simpler and more straightforward while maintaining effectiveness.
Solution Approach 2:
The lactic acid bacteria serve multiple functions simultaneously: they produce anti-inflammatory metabolites, modulate the immune system, and can be administered through various routes (oral, topical, intravenous). This multi-functionality simplifies treatment by replacing multiple specialized therapies with a single versatile biological agent that addresses various aspects of inflammation.
Data Source
Figure 1~2
Figure 3a~3b
Figure 3c~4
AI summary
The present invention relates to a novel strain of Lactococcus lactis subsp. lactis LB1022 strain and uses thereof. The Lactococcus lactis subsp. lactis LB1022 strain, which is a novel strain isolated from fermented dairy products, is a useful functional lactic acid bacterium with excellent acid tolerance, bile tolerance, and intestinal epithelial cell adhesion ability, and inhibits the production of any one inflammatory factor selected from the group consisting of nitric oxide (NO), tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), and interleukin-1β (IL-1β), and inhibits the gene expression of p65 or p50 in the nuclear factor kappa B pathway (NF-kB pathway), thereby exhibiting an excellent anti-inflammatory effect. Therefore, a composition comprising, as active ingredients, live bacteria, dead bacteria, or a culture medium thereof of the Lactococcus lactis subsp. lactis LB1022 strain may be utilized for the prevention, treatment, or amelioration of inflammatory diseases.